Cambrex Completes Large-Scale US API Expansion
PR95380
EAST RUTHERFORD, N.J., April 13, 2022 /PRNewswire=KYODO JBN/ --
Cambrex announced today the completion of a $50 million expansion of its
large-scale active pharmaceutical ingredient (API) manufacturing capabilities
at its Charles City, Iowa facility. The startup of the new manufacturing space
is the culmination of a two-year project, originally announced in 2020, to
increase the capacity of Cambrex's flagship API facility by 30%. The expansion
positions Cambrex with the largest and most advanced API facility in the United
States and ensures the long-term capacity to support Cambrex's existing
customer base and future growth supported by robust market demand.
"The opening of our Charles City facility expansion is a significant milestone
for Cambrex, solidifying our position as the leading U.S.-based provider of
small molecule APIs," said Thomas Loewald, CEO of Cambrex. "We continue to see
strong demand for high quality, U.S.-based development, and manufacturing of
new APIs, and we are excited to offer our existing and potential new customers
access to the best-in-class capabilities of our Charles City facility."
Following the expansion, Cambrex's Charles City facility has approximately 400
employees and an installed reactor capacity of over 25,000 gallons
(approximately 100 cubic meters). With multiple large-scale manufacturing
areas, the facility is able to reduce production timelines by manufacturing
multiple products with complex chemical syntheses in parallel. The facility is
located on a 45-acre property and produces a wide range of APIs and
pharmaceutical intermediates, including highly potent molecules and controlled
substances.
In addition to its expansion in Iowa, Cambrex continues to invest in additional
small- and mid-scale API manufacturing capacity at its Karlskoga, Sweden, and
High Point, North Carolina facilities. New capacity at those facilities is
expected to come online in late 2022 and mid-2023, respectively.
About Cambrex
Cambrex is a leading global contract development and manufacturing organization
(CDMO) that provides drug substance, drug product, and analytical services
across the entire drug lifecycle. With over 40 years of experience and a
growing team of over 2,200 experts servicing global clients from North America
and Europe, Cambrex is a trusted partner in branded and generic markets for API
and finished dosage form development and manufacturing.
Cambrex offers a range of specialized drug substance technologies and
capabilities, including biocatalysis, continuous flow, controlled substances,
solid-state science, material characterization, and highly potent APIs. In
addition, Cambrex can support conventional dosage forms, including oral solids,
semi-solids, and liquids, and has the expertise to manufacture specialty dosage
forms such as modified-release, fixed-dose combination, pediatric, bi-layer
tablets, stick packs, topicals, controlled substances, sterile, and non-sterile
ointments.
For more information, visit www.cambrex.com
Logo - https://mma.prnewswire.com/media/1723116/Cambrex_40_Years_Logo.jpg
SOURCE: Cambrex
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。